# Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

> **NCT03960645** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 62 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT03960645
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-28
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-08-18
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960645, "Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03960645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*